Not satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo ($ENDP) plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus ($VVUS). Endo is doubling the size of the Stendra salesforce, rolling out a new DTC effort, and keeping a close eye on inventory levels, which had built up too much for its taste. More from FiercePharmaMarketing